A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease

Area of Science:

• Biochemistry
• Genetics
• Immunology

Background:

• Pompe disease results from acid α-glucosidase (GAA) deficiency, with infantile forms being fatal if untreated.
• Recombinant human GAA (rhGAA) enzyme replacement therapy (ERT) improves survival but is ineffective in cross-reactive immunologic material (CRIM)-negative patients.
• CRIM-negative patients lack detectable endogenous GAA and mount an immune response against rhGAA, necessitating immune tolerance strategies.

Purpose of the Study:

• To develop and validate a rapid, blood-based assay for determining CRIM status in Pompe disease patients.
• To facilitate timely identification of CRIM status for optimized treatment strategies.
• To improve clinical outcomes for infantile-onset Pompe disease by minimizing treatment delays.

Main Methods:

• Development of a novel blood-based assay for CRIM status determination.
• Validation of the blood assay results against established methods like GAA Western blot analysis in fibroblasts and GAA sequencing.
• Analysis of assay turnaround time, aiming for results within 48 to 72 hours.

Main Results:

• The novel blood-based assay provides CRIM status results within 48 to 72 hours.
• Results obtained from the blood assay were confirmed by GAA Western blot analysis and GAA sequencing.
• The rapid classification of CRIM status is demonstrated as feasible.

Conclusions:

• A rapid blood-based CRIM assay can significantly reduce the time required for status determination compared to traditional fibroblast analysis.
• This assay facilitates prompt identification of patients who may not respond to standard ERT due to CRIM negativity.
• Early and accurate CRIM status assessment is crucial for initiating appropriate management and improving therapeutic efficacy in infantile Pompe disease.